Antibe Therapeutics Inc. Announces First Human Dose Of ATB-346 In Phase I Clinical Trial
6/27/2014 9:57:48 AM
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSXV:ATE) announced today that following the receipt of a No Objection Letter from Health Canada last week, its Phase I clinical trial was initiated today. This first clinical study of ATB-346, a drug with the promise of being a safer, anti-inflammatory painkiller, involves safety and pharmacokinetic evaluations in healthy human subjects and will be conducted in Montreal, Canada over the coming months.
Help employers find you! Check out all the jobs and post your resume.
comments powered by